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Abstract 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a systemic disease characterised by 
the formation of multiple renal cysts that adversely affect renal function. ADPKD shows 
significant progression with age when complications due to hypertension are most significant. The 
activation of the renin-angiotensin-aldosterone system (RAAS) occurs in progressive kidney 
disease leading to hypertension. The RAAS system may also contribute to ADPKD progression 
by stimulating signalling pathways in the renal cyst cells to promote growth and deregulate 
epithelial transport. This mini review focuses on the contribution of the RAAS system to renal cyst 
enlargement and the potential for antagonists of the RAAS system to suppress cyst enlargement 
as well as control ADPKD-associated hypertension. 
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Aetiology of Autosomal Dominant Polycystic Kidney Disease 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a  multisystem disease characterised 
by the development of multiple bilateral renal cysts and extra-renal manifestations such as 
cardiovascular abnormalities [1]. ADPKD affects 1 in 500 to 1 in 1000 people with a significant 
decline in glomerular filtration rate (GFR) and renal function usually occurring by the 4th decade 
of life [2]. ADPKD arises as a consequence of mutations in the PKD1 and PKD2 genes. Mutation 
of PKD1 causes cyst development to occur at an earlier age, resulting in worse survival and more 
severe disease progression compared to PKD2 mutation [1] [3]. The proteins encoded by the PKD1 
and PKD2 genes, polycystin-1 (PC1) and polycystin-2 (PC2), are both membrane bound 
glycoproteins and constitute a subfamily of transient receptor potential (TRP) channels (TRPP1 
and TRPP2 respectively) [2]. PC1 is found in plasma membranes at focal adhesions, desmosomes, 
and adherens junction sites contributing to epithelial integrity and extracellular matrix interactions 
[1]. Both PC1 and PC2 are also present in the plasma membranes of the primary cilia and form a 
complex that is sensitive to filtrate flow in the renal tubule [1]. The development of ADPKD is 
characterized by enlarged kidneys, the formation of multiple fluid filled cysts and abnormal protein 
deposition [4].  Cellular abnormalities that contribute to cyst enlargement include abnormal fluid 
secretion across the epithelial cells and epithelial cell proliferation [2]. Increased hydrostatic 
pressure inside the cyst encourages expansion, while cellular proliferation induces de novo cyst 
formation [2]. Premature mortality in patients with ADPKD is most often attributable to 
cardiovascular disease associated with hypertension [2]. Hypertension control by inhibiting the 
Renin-Angiotensin-Aldosterone system (RAAS) does not stop ADPKD patients from suffering 
end stage renal disease ESRD [5] , but it delays the onset of ESRD by 4 to 5 years [6]. 
 
Polycystin Mutation and Signalling in Polycystic Kidney Disease 
PC1 is a large, 460 kDa (4302 aa), multi-domain, transmembrane protein that functions as a cation-
permeable ion channel. PC2 is a smaller 110 kDa (968 aa) transmembrane protein that interacts 
with the carboxy-terminus of PC1 and other TRP channels, and also the ryanodine receptor-2. The 
carboxy-termini of PC1 and PC2 form a heterotrimeric G-protein binding domain that can initiate 
intracellular signalling cascades [1]. PC1 and PC2 are both integrated into a complex network of 
signalling pathways that can be deregulated in ADPKD. The structure of the renal cyst is the result 
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of deregulated solute transport that promotes the accumulation of fluid within the lumen [4], and 
also the proliferation of renal tubule epithelial cells due to EGFR and TGF-α overexpression [7]. 
PC1 upregulates p21 (waf1) by activating the JAK-STAT pathway, resulting in cell-cycle arrest at 
G0/G1 [2] [7]. PC2 directly interacts with Id2, a member of the helix-loop-helix (HLH) protein 
family to regulate cell cycle progression [7]. Mutation of PC1 and PC2 thus affects the proliferation 
potential of renal tubule cells. The overexpression and mislocation of EGFR in the apical 
membrane of cystic epithelial cells also stimulates cellular proliferation in the cyst cells through 
autophosphorylation of EGFR at Tyr416 [7].  
The PC1/PC2 complex is a flow-dependent mechanosensor that regulates intracellular Ca2+ and 
cAMP levels [8]. Mutation of PC1 or PC2 can lead to lower cytoplasmic Ca2+ concentrations [9]. 
At a low Ca2+ levels there is an increase in adenylyl cyclase-6 activity and a decrease 
phosphodiesterase activity, thereby increasing cAMP abundance [9] [7] [3]. cAMP is a strong 
mitogenic stimulant for cyst epithelial cells and is also implicated in the hyper-secretion associated 
with cyst formation. In normal individuals, the B-RAF proto-oncogene activity is inhibited by 
AKT. However, under Ca2+ restriction there is low AKT activation resulting in increased B-RAF 
kinase activity [7]. Stimulation of the B-RAF/MEK/ERK pathway will promote fluid 
accumulation and epithelial cell growth mediated by cAMP, so potentiating renal failure [7]. In 
renal cyst epithelial cells the basolateral Na+/K+-ATPase mediates Na+ extrusion in exchange for 
K+ uptake via the sodium-potassium-chloride cotransporter (NKCC1), which also drives 
basolateral Cl- entry [2]. Elevated PKA activity is associated with cAMP accumulation, and further 
stimulates Na+/-K+-ATPase activity that increases fluid accumulation in the cysts. 
 
Hypertension and Polycystic Kidney Disease  
Hypertension develops before loss of kidney function in most adults with ADPKD [10] [11], and 
is an important risk factor for progression to ESRD, cardiovascular morbidity and mortality [5]. 
Severe hypertension in ADPKD can cause left ventricular hypertrophy (LVH) and increase urinary 
albumin excretion, but this is normally observed before the changes in renal volume [3] [11]. 
Aldosterone levels become elevated at an early stage in ADPKD patients and negatively correlates 
with a decline in plasma creatinine clearance; however other studies have found that there is no 
direct correlation between RAAS activation and ADPKD [12]. The increasing use of 
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antihypertensive therapy in ADPKD has been shown to reduce the incidence of ESRD [13]. 
Clinical trials have demonstrated variations in the efficacy of aggressive blood pressure control in 
delaying ESRD. A number of studies found that aggressive blood pressure control delays the 
progression of chronic kidney disease (CKD). These include the ESCAPE study which found that 
aggressive blood pressure control in children with CKD resulted in better GFR and reduced 
progression to ESRD [14], and also a study conducted on an elderly population in Denmark which 
concluded that a reduced incidence of ESRD in this population was associated with an increase in 
the prescription rates for anti-hypertensive drugs especially RAAS blockade with angiotensin 
converting enzyme (ACE) inhibitors and angiotensin receptor blockade (ARB). Other studies such 
as the MDRD study found limited benefit in aggressive versus normal blood pressure control [15] 
while other studies found no benefit beyond that of normal blood pressure control [16,17]. ACE 
inhibition is used as the first line treatment for ADPKD and a number of studies have found that it 
adequately achieves hypertension control in most patients [18-20]. However, a recently published 
large scale study suggests that the delayed need for renal transplantation in ADPKD-associated 
ESRD is due factors other than the renoprotective effects of hypertension control [21].  
Short-term therapy with an ACE inhibitor improves renal blood flow, reduces proteinuria and 
delays renal failure [10]. Diuretics have equivalent efficacy to ACE inhibitors in controlling 
hypertension and are the first line therapy where there has not been a significant loss in renal 
function [6], however patients treated with diuretics have a faster decline rate in GFR compared 
to those treated with ACE inhibitors [10] [11]. ACE inhibitors such as Enalapril and Ramipril 
effectively control blood pressure and proteinuria in hypertensive ADPKD patients but do not 
show any significant benefit in normotensive ADPKD patients [10]. Generally ACE inhibitors are 
more effective than Ca2+ channel blockers such as dihydropyridine in controlling albuminuria, 
preserving creatinine clearance and reducing ventricular hypertrophy [6] [11]. The use of ACE 
inhibitors alone may result in incomplete blockade of RAAS because angiotensin II may be 
produced through the chymase pathway within renal cysts, and so stimulate aldosterone release 
independent of ACE activity [10] [22].  The use of ARB may circumvent angiotensin II activation 
at the renal cyst, however Lisinopril (ACE inhibitor) and Telmisartan (Angiotensin II receptor 
blocker) have similar efficacy in controlling blood pressure and lowering urinary aldosterone 
excretion [20]. 
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RAAS Involvement beyond Hypertension Control 
RAAS activation contributes to the pathophysiology of ADPKD not only through the promotion 
of hypertension, but also by directly stimulating the growth of renal cysts [5]. Angiotensin II and 
aldosterone both contribute to ADPKD-associated hypertension and potentially to cyst 
development. Angiotensin II promotes cellular proliferation and vascular hypertrophy [3], so 
stimulating cyst enlargement, local kidney ischemia and disrupting the renal architecture [2] [10]. 
Renal ischemia can also lead to adenosine release that increases afferent renal nerve traffic [23]. 
The tubular dysfunction caused by structural changes in the kidney can result in Na+ retention and 
vascular remodelling [3]. There is an increase in the urinary detection of monocyte chemoattractant 
protein (MCP)-1 and altered growth of cardiovascular tissue, especially in the intima media of the 
carotid artery [3]. Such cardiovascular complications are a major mortality risk factor for ADPKD 
patients [11]. Renin protein and mRNA are found in ADPKD cyst fluid and may facilitate the local 
activation of the RAAS cascade in a manner that is ACE-independent [22]. This action is not 
controllable with ACE inhibitors and may represent an alternative target for therapeutic 
intervention. It is not clear what contribution is made by renin-independent RAAS activation and 
aldosterone release to ADPKD-associated hypertension.  
  
The activation of the RAAS cascade culminates in aldosterone release from the adrenal cortex. 
The mineralocorticoid receptor (MR) is a ligand-dependent transcription factor that modulates the 
expression of target genes and initiates the activation of protein kinase signalling cascades. MR is 
expressed by the aldosterone-responsive cells of the distal nephron. The transcriptional action of 
aldosterone promotes the expression of the -subunit of the Na+/K+-ATPase to promote Na+ 
conservation in normal tubular cells. In ADPKD enhanced Na+/K+-ATPase activity may contribute 
to fluid secretion into the cyst and so promote cyst enlargement. Aldosterone also stimulates 
EGFR-coupled signalling cascades in MR-expressing cells [24]. The binding of aldosterone to MR 
can initiate a cSrc signalling cascade that activates EGFR through the release of heparin-bound 
EGF from the cell surface [25]. Activated EGFR stimulates renal fibroblast proliferation and the 
development of fibrotic lesions in the kidney [25]. EGFR transactivation by aldosterone can also 
promote proliferation in undifferentiated renal tubule cells [24]. Renal cyst formation is a 
combination of epithelial cell proliferation and ion transport dysregulation. Aldosterone can induce 
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several signalling cascades which include PKA, PKCα, PKD1, ERK1/2 mitogen activated protein 
(MAP) kinase that enhance cell multiplication and modify ion transport activities in renal cells 
[24].  
The HALT clinical trials included the objectives of evaluating the contributions of RAAS 
activation and blood pressure control on both the cardiovascular and renal manifestations of 
ADPKD [5]. Of particular importance was understanding whether controlling blood pressure at 
the very early stages of the disease, in advance of a significant decline in renal function may help 
to slow progression to ESRD in younger patients. While aggressive blood pressure control did 
slow kidney enlargement and albuminuria, the study found that combined ACE inhibition and 
angiotensin II receptor antagonism did not attenuate the increase in kidney volume beyond that 
achieved by ACE inhibition alone [26]. Blood pressure control was most effective in slowing 
progression in male patients and patients with the most enlarged kidneys. The patients on dual 
therapy did have a reduced risk of hospitalization over the study and were less likely to develop 
kidney stones [26]. The study also looked at the effect of ACE inhibition and ARB on progression 
to ESRD and eGFR decline in advanced ADPKD, and found that dual therapy did not confer any 
benefit beyond that achieved with ACE inhibition alone [20].  Further investigation of the specific 
synergistic actions of ARB in combination with ACE antagonism may provide more information 
on how the intrarenal RAAS and localized activation of angiotensin in renal cysts contributes to 
cyst development independently of the systemic RAAS [12].    
Since combined ACE antagonism and ARB treatment have very limited synergistic action in 
attenuating ADPKD progression, the question remains whether direct antagonism of   MR may be 
used effectively in combination with ACE antagonism. Animal models may also give us more 
information on the diverse actions of aldosterone in ADPKD. The Lewis Polycystic Kidney (LPK) 
rat model displays cardiovascular and renal pathophysiological changes that are associated with 
human ADPKD, including early elevation of plasma aldosterone and plasma creatinine [27]. MR 
antagonism with spironolactone achieved an effective control of hypertension in this animal model 
within 12 weeks. Spironolactone treatment also helped to restore renal function with the 
normalization of polydipsia, proteinuria and polyuria. Plasma creatinine levels were also reduced 
indicating a restoration of GFR. In spite of this enhancement in kidney function with 
spironolactone treatment, there was no impact on the gross morphology of the kidneys in the LPK 
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rats [27]. Spironolactone had no significant effect on kidney volume, renal fibrosis or on cyst 
growth.  This observation raises the question of exactly how is spironolactone stabilizing renal 
function in this model of ADPKD. The contribution of aldosterone to declining kidney function in 
the LPK model may also be different to its contribution in the human disease. The LPK phenotype 
arises because of mutation in the NIMA-related kinase 8 (Nek8) gene rather than in PC1 or PC2. 
Nek8 is a serine/threonine protein kinase that at is associated with the primary cilium and co-
immunoprecipitates with PC2 [28]. Nek8 phosphorylates PC2 and regulates the normal 
localization of PC1 and PC2 at the primary cilium. Consequently, the spectrum of deregulated 
signalling in the LPK model may be different to that seen in ADPKD, and the scope for aldosterone 
to accelerate disease progression may rely upon alternative mechanisms in different signalling 
backgrounds depending on whether PC1 and PC2 are mutated, improperly phosphorylated or 
mislocated. A recent study has found that activation of an intrarenal renin-angiotensin pathway is 
stimulated on PC1 knock-out and primary cilium dysfunction [29]. 
Conclusion 
The importance of antagonizing the RAAS system to control ADPKD progression and associated 
hypertension is evident; however, we need to understand better how aldosterone antagonism in 
particular can help to directly mitigate the renal effects of this disease. Aldosterone participates in 
a broad spectrum of signalling actions in renal tubular cells which include regulation of transporter 
activity, cell differentiation and growth. There is considerable overlap between the signalling 
cascades coupled to the normal function of the PC1 and PC2 proteins, and the actions of 
aldosterone in the distal nephron. The full contribution of systemic or intrarenal RAAS over-
stimulation and the resultant deregulated signalling and transporter activity in ADPKD cyst cells 
remains to be established.  
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